Difficulties in conducting an epidemiological study for endocrine disrupting chemicals

Selichiro Yamamoto, Ph.D Statistics and Cancer Control Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Japan

The 8th International Symposium on Endocrine Disruption in Okinawa, December 4-6

Evidence level of epidemiologic studies

	Evidence Level	Study Design	Data collection	Unit	# subjects	Period	Cost
	High	Randomized Controlled Trial	Pro- spectiv e	Individual	1,000- 100,000	10y rs	>\$10 mil
21. 22		Cohort study/Nested case-control study	Pro- spectiv e	Indiv idual	10,000- 1,000,000	10y rs	\$10 mil
		Case-control study	Retro- spectiv e	Indiv idual	100-1000	2-3y rs	\$1 mil
		Cross-sectional study	Cross sectional	Indiv idual	100-1000	1yr	<\$0.1 m
Contraction of the local distribution of the		Ecological study	Cross sectional	Population	<100 pops	0	0
	Low	Time series	Cross sectional	Population	One population	0	0
		Expert opinion	-	-	-	-	-

Quality of evidence depends on the accuracy of exposure measurements

- Questionnaire vs. Biological marker
 - Quantitative vs. qualitative
 - Category vs. Dose response
 - Questionnaire does not take into account
 - Inter-individual variation in metabolism
 - many exposure pathway
- Measurement error in exposure assessment
 Validity of EDC in serum/adipose tissue
 Confounded by endogenous and other exogenous estrogen exposure

Quality of evidence also depends on the study design Prospective vs. retrospective Selection bias Interventional vs. observational Confounder assessment Number of high quality studies Consistency of the results I would rather emphasize the difficulties in conducting epi studies

Summary of EDC epi studies Report from MHLW WG for health effects of EDC

- Epidemiological study Searched by PubMed
 - Disease AND human AND
 - (insecticides OR pesticides OR chlorinated hydrocarbons OR pesticides OR chlorinated hydrocarbons OR pcbs OR bisphenol OR phenol OR phthalate OR styrene OR furan OR organotin OR diethylstilbestrol OR ethinyl estradiol)
 - Until 2004.10.31
- Diseases
 - Cancer
 - Breast, endometrium, ovary, prostate, testis, thyroid
 - Other diseases
 - Thyroid, hypospadias, cryptorchidism, child development, sperm count, allergy

List of the studies conducted for diseases and EDC by study design

1 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Total	Cohort	Nested	Retro.	Cross	Eco-	For
	TUT	CONDIT	CaCo	CaCo	sectional	logical	Japanese
Breast	72	8	14	38	6	6	
Endometrium	2	0	0	2	0	0	0
Ovary	8	3	0	2	0	3	0
Prostate	24	10	3	6	0	5	0
Testis	19	7	0	9	0	3	0
Thyroid	6	3	0	0	0	3	0
hypospadias	8	2	0	6	0	0	0
cryptorchidism	13	1+1	0	11	0	0	0
Child develop.	39	35	0	1	2	1	1
endometriosis	6	0	0	4	2	0	0
Thyroid function	15	2+1	0	1	10	1	2
Sperm count	30	1	1	9	18	1	1
allergy	5	3	0	1	1	0	0

Points to consider 1

Why are there many ecological studies in cancer but not in other diseases ?
Monitoring system for incidence and mortality in population differs among diseases
Cancer: incidence from cancer registry, mortality from vital statistics
Other diseases: very few diseases have disease registry, vital statistics is no use for nonfatal diseases


Points to consider 2

Why are cohort studies common ?

- Exposure of interest is mainly DES or occupational exposure such as pesticide users
- Retrospective definition of cohort
 - Retrospective definition of exposure, no biological measurements
 - "historical cohort" study
- Why can nested case-control study (=prospective study using stored biological specimen) be done only for cancer ?
 - Use of already existing multipurpose cohort
 - Stored sample, other exposures, and endpoint ascertainment system can be used
 - Example: Nurses' Health Study

Difficulties in conducting cohort study in Japan

An example from JPHC Study



Self-administered questionnaire - JPHC Study, baseline survey -

• 14 pages color-printed questionnaire (Partly modified for Cohort II) ➢Past medical/Family history ➤Smoking and drinking ➢Physical activity ≻Stress and social support Residential / Occupational history Chemical and other environmental exposure ➢ Personality ➢ Reproductive history ➢Diet ≻44 or 46 food item FFQ >4 or 5 frequency categories ≻Some with portion size ► Validation study was done for ~500 subjects



Cohort

	142天三 袁《合公	選 1-1日	<u>원</u> 3-18	日之云: 3 毎日
わん類(インスタント製品を除く)	Я.	1	2	-3
(ンスタン)のめん類		1.	2	3
(シ (夏子パン、調理パンを含む)	18	Ł	2 .	3
(ターやマーガリン	8	1	2.	3
6 fe	6	1	2	3
こうれんそう、存着など、東が緑の野菜	8	L.	2.	3
えとん、かほちゃなどの首色野菜		L	*	3
の線(目底、大胆トマト、キュウリなど)の根本	W.	1	2	3
レッシングやマヨキーズ	- M.	L.	2	1
(物:0篇・ぬかゆ考など野菜の液物)	- 00	1	2	3
ភភព	0	F	- 21	3
つまいも、じゃかいもなどのいる糊	0	t	2	3
り、わかめ、昆布などの海卒間	11	1	2	- 3
sz + szas - akis - akis		L.	2	-3
(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(t.	2	1
1 =	U.	L	2	3
乳や乳製品 (チーズを除く)		1	2	3
-1		- F.	2	1
南	0	1	2	3
19)		1	2	1
6 (q	a)	1	2	3
	0.	1	3	3
**** (きも)	0	10	- 2%	-3
鮮な協介編	. 0	E	2	1.
魚(わぎしなど)・塩魚(塩さけなど)	0	1	2	4
液魚車(たらこ、すじこ、いくらなど)	0	10	2	3
からや練りうに		D.	2	3

(FFQ 44 items)



- JPHC Study, baseline survey -

- 10 ml peripheral blood in heparinized tube
- centrifuged within 12 hours
- 3 tubes (1 ml) for plasma
- 1 tube (1 ml) for buffy layer
- stored at -80



Conduct of questionnaire survey

- >80% participation rate for 140,000 subjects
 - Questionnaire delivered to house and collected several days later
 - >1,000 coordinators
- ~35% Participation rate for Blood sampling
 Collected at the health check-up examination
 Informed consent and voluntarism in Japanese
 Costly

Events collected during the follow-up

 Mortality: Population registry at local municipalities Death certificates at public health center
 Migration: Population registry at local municipalities
 Incidence (cancer, cerebrovascular disease and ischemic heart disease): Medical records at local hospitals
 Population-based registry (Prefecture-wide) for cancer

Registration Form for Cancer, CVD, IHD

		コホート研究班 登録 票
ED##		發業 未全
カキテ書号		
共 名		_ = = 1. # ===== #= 1. # ===== #============================
\$ W		
亲张单开日	9% <u>+ /</u>	н
正日小茶茶	₹£₹3,	_1
R N S E	1. 総称数据 2. 高級単位 ※、その後(3. 施設出版 4. 死亡 原 5. アンケーキ3
非 图力 25	1. 集化所用 1. 相称单 6. 在0年1	3. 1. R. I. F. H. S. R. N.
市 東 名 (取用規定)		観望コード With Sector
		変換コーア れいかけい
	1. WHE 2. IEW	3、所属リンパ語 4、薬剤発達 5、油3
TWMSM	TN	
8 N	1. 単気統分(M22名 2. 売加やまたは利利期的中 3. 死亡 4. その後	
s ×		
R 静学 記入 I	1 76 ¥ Л.	0 883

	1	厚生者 脳 卒				115	
1.7.2.0			3		所名	-	
カルテ節句	2						
武吉			e	1. 册 2. 女	住布川	8 <u>R</u>	
住所							
皇室年月日	午成 年		H				
动肥东为日	平政 平	н	,ti				
化脱方法	1. 現成登録 年、その後二	1.8169	3, 8	ana.	4.	ec s	5. 727-1
今回の身代	1, 20120	3. 8	9.0		赤	-	
	SEDOAL E A N E	股高 1. 清明 2. 清明と 3. 規則	9 Hen 9 See 2		antes.	enH <i>x</i> NERS	(#)
ta e n M	<u>発生的のあた</u> <u>在 読 例 前</u> 41 <u>補 録 例 市</u> <u>注 訳 例 市</u>	8.0 1. #H 2. #H 3. #	mH # divid Qu (Bu C d) GA V (S) (Qu GA # S) (Qu GA # 1, 1 3, 1	くと思るか を用した 単数に方 間にもの 単し にし	(NA) 593 594 519 9,1	18 E R J) 6 M	(#)
数 年 州 从 C 丁 陳 永 (長収羽)	<u>REBORN</u> <u>E M H H</u> 11 <u>H M H H</u> <u>2 H H H</u>	 総点 1. 法用 2. 活动と、 3. 税休 4. 税休 5. 行助 5. 行助 1. 作 つ 	mH # はいえない 使ってお 毎~ひ大さ (低い借み# 見、1 3、5	(2003) 2011年20 (2011年20) (第二年20) 第二年 11日 11日 11日 11日 11日 11日 11日 11日 11日 11	(NA) 593 594 519 9,1	18 E R J) 6 M	
ta e n M	<u>REBORN</u> <u>E M H H</u> 11 <u>H M H H</u> <u>2 H H H</u>	8.0 1. #H 2. #H 3. #	mH & はいえない 家々でお 都らや大お 派い様み# え、1 3、1 第 単	(()m30 なかにの) 利用に分 間にもの) 町 し れ し 町 一次 刊 町 一次	(NA) 593 594 519 9,1	(11-1) (1) (1) (1) (1)	*) * # 5 5 : 2==849 : 3=859 : 3=595 : 3=5955 : 3=5955 : 3=5955 : 3=59555 : 3=59555 : 3=59555 : 3=5955555 : 3=5955555555555555555555555555555555555
а ж л Ц с т ж я (еди) в ж р	REPORT K. M. N. N. K. M. N. N. N. R. M. R. N. N. M. M. R. N. N. M. M. R. N. N. M. M. N. N. M. M. N. N. M. M. N. N. M. N. N. N.	 総当 上: 市田 上: 市田 二: 市田 二: 市田 二: 市田 二: 市田 二: 市日 二	m)日本 はいえない 他へてお 年の大さら 編い事本本 し、1 日 日 一 「 「 「 で 大領品」 () 「 で 大領品」 ()	(()m30 なかにの) 利用に分 間にもの) 町 し れ し 町 一次 刊 町 一次	(NA) 593 594 519 9,1		4 8 A 3
В ж л Ц С Т в д Г ж д В ж ж А 1948 В 364 8 3 545 8 3 545 8 3 545 8 3 545 8 3 545 8 3 545 8 3 545 8 3 54 8 3 5 8 3 5 8 3 5 8 3 5 8 3 5 8 3 5 8 3 5 8 3 5 8 3 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<u>SECONAL</u> <u>6 A M M M</u> 	### 1. ### 2. ### 4. (*## 5. **## 6. (****) 1. 作 7. **## 7. **## 7. **## 7. **## 7. **## 7. **## 7. ***# 7. ***# *********************	m)日本 はいえない 他へてお 年の大さら 編い事本本 し、1 日 日 一 「 「 「 で 大領品」 () 「 で 大領品」 ()	(()m30 なかにの) 利用に分 間にもの) 町 し れ し 町 一次 刊 町 一次	(NA) 593 594 519 9,1		 # # A 2 2 = 64 5 = 66 5 = 66 7 = 66 7 = 66 7 = 66 1 = 260 1 = 260 1 = 260 1 = 260

	厚生省コホート研究班 心筋梗塞・急性死登録票
1D#形	· · · · · · · · · · · · · · · · · · ·
11日文書号 正 25 作 所	
政府年月日	<i>रस</i> म स स
診動年月日	₹ <u>₹</u> 00
把握方法	1.84224 2.8210 3.82024 4.842 5.7 $^{++}$ -1.80 1.7 $^{++}$ 1.91
今前の発作	1. 8002作 2. 再是作 9. 手 利
11 (# 17 1)	前期 1. 次少(元)((2.1)()(2.4), 0. 10(1.1.)、小規定用、二,不可) 2. 用し 3. 不明
11 F 15 5	CREM CPX LOB COT # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # #
	1. 廃実など等発業(4電圧爆発発化による) 1. 可教授のあるの影響素(国際な低による) 小田教授の決策(1. 首・第二2、下・夜)、石、田 少、不 再
再开放使法	1. #1 (PICA, PICE, 新新作) 2. 第1. 9. 美 明
息 性 化C年月日 NCネの時間	 死 登 録 (10時期に穴の周囲子系の2年) 10歳 年 共 目 1.5歳には周辺内 1.5歳1-30時期20点

Difficulties in follow-up ascertainment of diseases

No good existing source of monitoring diseases Only cancer registry but quality is not so good Voluntary report from hospitals No incentives of hospital doctors Active collection by hospital visit Many hospitals should be covered in study areas (esp. if Tokyo, Osaka, etc.) Self-report is not reliable Poor: cancer, cardiovascular diseases Moderate: Diabetes Mellitus Health check-up exam Good: Cataract

Difficulties in follow-up

Many resources are needed

 money, organization, people

 Poor Social understanding for research

 Privacy protection regulations and informed consent
 No unique ID such as social security number

Requir	ed events	and sar	mple size	e for 10			
yea	ar follow-u	up in cru	ude analy	ysis			
Rate in the	e 1st exposure	Relative F	Relative Riks in the 5th quintile				
quintile	(1/100,000)	1.5	2.0	3.0			
1	n	3,979,000	1,225,000	434,000			
	# of death	497	184	87	2		
5	n	796,000	245,000	87,000			
	# of death	497	184	87			
10	n	398,000	123,000	43,000			
	# of death	497	184	87			
20	n	199,000	61,000	22,000	é		
	# of death	497	184	87			
30	n	133,000	41,000	14,000	į,		
	# of death	497	184	87			
100	n	40,000	12,000	4,000			
	# of death	497	184	87			

2 sided alpha=0.05 and power=80%

Why few studies conducted in Japan?

- Poor availability of disease monitoring system
- Costly
- Few existing cohort with sufficient cases and biological specimen

Other available designs ?

List of the studies conducted for disease and EDC by study design

1 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Total	Cohort	Nested	Retro.	Cross	Eco-	For
12 12 12 12	TUT	CONDIC	CaCo	CaCo	sectional	logical	Japanese
Breast	72	8	14	38	6	6	
Endometrium	2	0	0	2	0	0	0
Ovary	8	3	0	2	0	3	0
Prostate	24	10	3	6	0	5	0
Testis	19	7	0	9	0	3	0
Thyroid	6	3	0	0	0	3	0
hypospadias	8	2	0	6	0	0	0
cryptorchidism	13	1+1	0	11	0	0	0
Child develop.	39	35	0	1	2	1	1
endometriosis	6	0	0	4	2	0	0
Thyroid function	15	2+1	0	1	10	1	2
Sperm count	30	1	1	9	18	1	1
allergy	5	3	0	1	1	0	0

Points to consider 3

New study is necessary
 To obtain sufficient biological materials
 Prospective study takes cost and time
 evidence level should be as high as possible

Available design is retrospective casecontrol study

An example from Childhood leukemia Study

Objective


 To investigate the factors related to the incidence of childhood *LK*

 Study design

 Population-based
 retrospective case-control study

 Factors of interest

 Life-style factors and family history
 Electric Magnetic Field exposure
 Chemical and other environmental exposure



Kabuto et al. Int J Cancer (in press)

Biggest difficulty: Low participation rate

312 cases and 603 controls from all over Japan
 Originally 500 cases and 3 matched controls were planned
 Case participation rate: 50%

- Case referrals from childhood leukemia group
- Accessibility to cases was difficult
- ~80% participation once referred

Control participation rate: 30%

- 10 Control candidates were selected from the resident registration system
 - Handwriting from the list
- Participation request by Mail
 - ~30% is typical for mail survey
 - 30% cannot rule out selection bias
 - Validation study to prove no selection bias

Retrospective Case-Control study

Population-based

- Better but difficult to sample control randomly from the population which case arises
 - Difficulty in identifying source population for cases
 - Difficulty in random sampling
 - List making, rejection to participate in the study
- Costly to obtain measurements at home
- Not feasible in Japan
- Hospital-based
 - More feasible but not a random sample from the population which case arises
 - No assurance of randomness
 - Risk of exposure is underestimated if disease of control subjects is associated with the exposure
 - Feasible in Japan

Historical cohort study		Retrospective case- control study
Drug use/occupational exposure in category	Exposure	Biological measurements but after diagnosis
Few information	Confounder	Questionnaire but after diagnosis
Same	Population which cases and controls occur	No assurance
Multiple if registry or data is available	Target Diseases	One
~1 year	Research Period	Several years
Several hundreds	# of cases needed	Several hundreds
># cases x 100	Number of subjects	# cases x 2-6
<\$ million	Cost	\$ several million
accuracy of exposure & confounder information	Quality depends on:	selection bias & confounder information

Summary of difficulty and proposal for conducting Prospective study

Historical cohort study

- Difficulty depends on collection of incidence data
- Exposure information may be obtained if past exposure is identified retrospectively such as DES use or occupational exposure
- Nested case-control studies (w/biological specimen)
 - New study is very costly
 - Use of existing cohort studies is practical if it exists
- Collaboration with other epidemiologists is critical

Summary of difficulty and proposal for conducting retrospective study Case-control study Population-based case-control studies Impossible if the list of population is not available Low participation rates does not assure no selection bias Hospital-based case-control studies Most feasible design but no assurance of no selection bias, i.e. comparability of cases and control Collaboration with clinicians is critical

Thank you for your attention!